Retrospective Cohort Study
Copyright ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2024; 16(3): 761-772
Published online Mar 15, 2024. doi: 10.4251/wjgo.v16.i3.761
Epidemiology, therapy and outcome of hepatocellular carcinoma between 2010 and 2019 in Piedmont, Italy
Christian Bracco, Marta Gallarate, Marco Badinella Martini, Corrado Magnino, Salvatore D'Agnano, Roberta Canta, Giulia Racca, Remo Melchio, Cristina Serraino, Valentina Polla Mattiot, Giovanni Gollè, Luigi Fenoglio
Christian Bracco, Marco Badinella Martini, Corrado Magnino, Salvatore D'Agnano, Roberta Canta, Giulia Racca, Remo Melchio, Cristina Serraino, Valentina Polla Mattiot, Giovanni Gollè, Luigi Fenoglio, Department of Internal Medicine, Santa Croce e Carle General Hospital, Cuneo 12100, Italy
Marta Gallarate, Department of Medical Sciences, "City of Health and Science" University Hospital, Torino 10100, Italy
Author contributions: Bracco C, Gallarate M and Fenoglio ML conceived and designed the research study; D’Agnano S, Canta R and Ruocco I performed the data collection; Magnino C, Casazza G, Racca G and Melchio R analyzed and interpreted the data; Bracco C, Gallarate M and Badinella Martini M wrote and edited the manuscript; All authors read and approved the final version of the manuscript.
Institutional review board statement: This study was approved by the Ethics Committee of “Santa Croce e Carle” General Hospital of Cuneo and the Cuneo 1 Local Health Authority.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: None of the authors have any potential conflicts of interest to disclose.
Data sharing statement: The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Salvatore D'Agnano, MD, Doctor, Department of Internal Medicine, Santa Croce e Carle General Hospital, Via Michele Coppino 26, Cuneo 12100, Italy. dagnano.s@ospedale.cuneo.it
Received: October 19, 2023
Peer-review started: October 19, 2023
First decision: December 4, 2023
Revised: December 19, 2023
Accepted: December 28, 2023
Article in press: December 28, 2023
Published online: March 15, 2024
Processing time: 144 Days and 21.7 Hours
Core Tip

Core Tip: Hepatocellular carcinoma (HCC) is the most common primary liver malignancy and the second leading cause of cancer deaths worldwide. HCC patients have increasingly complex and constantly changing characteristics, thus up-to-date and comprehensive data are fundamental. In this study, we analyzed the epidemiology and main clinical characteristics of 328 HCC patients in a referral hospital in the northwest of Italy between 2010 and 2019. We found that hepatitis C virus infection was the most common etiology and most patients presented with advanced stage disease and a poor prognosis.